Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 2
1992 6
1993 3
1994 1
1995 1
1996 1
1997 2
1998 3
1999 2
2000 3
2001 3
2002 5
2003 6
2004 2
2005 1
2006 3
2007 3
2008 2
2009 3
2010 4
2011 3
2012 4
2013 5
2014 2
2015 3
2017 3
2018 7
2019 3
2020 10
2021 7
2022 4
2023 4
2024 3
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

106 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.
Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J; ECHELON-1 Study Group. Connors JM, et al. N Engl J Med. 2018 Jan 25;378(4):331-344. doi: 10.1056/NEJMoa1708984. Epub 2017 Dec 10. N Engl J Med. 2018. PMID: 29224502 Free PMC article. Clinical Trial.
Fludarabine, Cytarabine, Granulocyte Colony-Stimulating Factor, and Idarubicin With Gemtuzumab Ozogamicin Improves Event-Free Survival in Younger Patients With Newly Diagnosed AML and Overall Survival in Patients With NPM1 and FLT3 Mutations.
Russell NH, Wilhelm-Benartzi C, Othman J, Dillon R, Knapper S, Batten LM, Canham J, Hinson EL, Betteridge S, Overgaard UM, Gilkes A, Potter N, Mehta P, Kottaridis P, Cavenagh J, Hemmaway C, Arnold C, Freeman SD, Dennis M; PORTEC Study Group. Russell NH, et al. J Clin Oncol. 2024 Apr 1;42(10):1158-1168. doi: 10.1200/JCO.23.00943. Epub 2024 Jan 12. J Clin Oncol. 2024. PMID: 38215358 Free PMC article. Clinical Trial.
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Othman J, Potter N, Mokretar K, Taussig D, Khan A, Krishnamurthy P, Latif AL, Cahalin P, Aries J, Amer M, Belsham E, Conneally E, Craddock C, Culligan D, Dennis M, Duncan C, Freeman SD, Furness C, Gilkes A, Gkreka P, Hodgson K, Ingram W, Jain M, King A, Knapper S, Kottaridis P, McMullin MF, Mohite U, Ngu L, O'Nions J, Patrick K, Rider T, Roberts W, Severinsen MT, Storrar N, Taylor T, Russell NH, Dillon R. Othman J, et al. Among authors: culligan d. Leukemia. 2023 Oct;37(10):2066-2072. doi: 10.1038/s41375-023-01994-x. Epub 2023 Aug 9. Leukemia. 2023. PMID: 37558736 Free PMC article.
Induction chemotherapy and molecular MRD influence outcomes in KMT2A-rearranged AML.
Othman J, Potter N, Freeman SD, McCarthy N, Jovanovic J, Runglall M, Canham J, Thomas I, Johnson S, Gilkes A, Cavenagh J, Kottaridis P, Taussig D, Arnold C, Hemmaway C, Culligan D, Overgaard UM, Dennis M, Burnett AK, Russell NH, Dillon R. Othman J, et al. Among authors: culligan d. Blood. 2025 Oct 9;146(15):1862-1867. doi: 10.1182/blood.2025029556. Blood. 2025. PMID: 40768751 Clinical Trial.
Inflammatory profile of lower risk myelodysplastic syndromes.
Topping J, Taylor A, Nadat F, Crouch S, Ibbotson A, Čermák J, Symeonidis A, Tatic A, Langemeijer S, Hellström-Lindberg E, Culligan D, Garelius HG, Ashcroft J, Nga E, Parker J, Kolade S, McDermott MF, De Witte T, Bowen D, Smith A, Cargo C, Savic S; ImmunAID consortium and EU‐MDS consortium. Topping J, et al. Among authors: culligan d. Br J Haematol. 2024 Sep;205(3):1044-1054. doi: 10.1111/bjh.19530. Epub 2024 May 21. Br J Haematol. 2024. PMID: 38772913 Free article.
Survival and quality of life in patients with lower risk myelodysplastic syndromes exposed to erythropoiesis-stimulating agents: an observational cohort study.
Garelius HKG, Bagguley T, Taylor A, Fenaux P, Bowen D, Symeonidis A, Mittelmann M, Stauder R, Čermák J, Sanz G, Langemeijer S, Malcovati L, Germing U, Sanhes L, d'Aveni M, Culligan D, Kotsianidis I, Koinig KA, van Marrewijk C, Crouch S, deWitte T, Smith A, Hellström-Lindberg E. Garelius HKG, et al. Among authors: culligan d. Lancet Haematol. 2025 Feb;12(2):e128-e137. doi: 10.1016/S2352-3026(24)00350-8. Lancet Haematol. 2025. PMID: 39909656 Free PMC article.
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial.
Lewis DJ, Jerkeman M, Sorrell L, Wright D, Glimelius I, Poulsen CB, Pasanen A, Rawstron A, Wader KF, Morley N, Burton C, Davies AJ, Lagerlöf I, Dalal S, De Tute R, McNamara C, Crosbie N, Toldbod HE, Sanders J, Allgar V, Aroori S, Warner M, Scully C, Wainman B, Christensen JH, Riise J, Sonnevi K, Bishton MJ, Eyre TA, Rule S; ENRICH investigators. Lewis DJ, et al. Lancet. 2025 Oct 25;406(10514):1953-1968. doi: 10.1016/S0140-6736(25)01432-1. Epub 2025 Oct 3. Lancet. 2025. PMID: 41052510 Free PMC article. Clinical Trial.
The genomic and clinical consequences of replacing procarbazine with dacarbazine in escalated BEACOPP for Hodgkin lymphoma: a retrospective, observational study.
Santarsieri A, Mitchell E, Pham MH, Sanghvi R, Jablonski J, Lee-Six H, Sturgess K, Brice P, Menne TF, Osborne W, Creasey T, Ardeshna KM, Baxter J, Behan S, Bhuller K, Booth S, Chavda ND, Collins GP, Culligan DJ, Cwynarski K, Davies A, Downing A, Dutton D, Furtado M, Gallop-Evans E, Hodson A, Hopkins D, Hsu H, Iyengar S, Jones SG, Karanth M, Linton KM, Lomas OC, Martinez-Calle N, Mathur A, McKay P, Nagumantry SK, Phillips EH, Phillips N, Rudge JF, Shah NK, Stafford G, Sternberg A, Trickey R, Uttenthal BJ, Wetherall N, Zhang XY, McMillan AK, Coleman N, Stratton MR, Laurenti E, Borchmann P, Borchmann S, Campbell PJ, Rahbari R, Follows GA. Santarsieri A, et al. Among authors: culligan dj. Lancet Oncol. 2025 Jan;26(1):98-109. doi: 10.1016/S1470-2045(24)00598-9. Epub 2024 Dec 12. Lancet Oncol. 2025. PMID: 39674188 Free article.
Guideline for the first-line management of Classical Hodgkin Lymphoma - A British Society for Haematology guideline.
Follows GA, Barrington SF, Bhuller KS, Culligan DJ, Cutter DJ, Gallop-Evans E, Kassam S, Osborne W, Sadullah S, Townsend W, Uttenthal BJ, Collins GP; British Society for Haematology. Follows GA, et al. Among authors: culligan dj. Br J Haematol. 2022 Jun;197(5):558-572. doi: 10.1111/bjh.18083. Epub 2022 Feb 22. Br J Haematol. 2022. PMID: 35191541 Review.
106 results